Vyteris Says Pain Relief Trial Successful
Posted on: Monday, 19 March 2007, 15:01 CDT
Vyteris has reported that osteoarthritis pain drug LidoSite provided better pain relief to the majority of patients then usual topical analgesics in a phase IV trial.
The US-based company said that more than 73% of patients receiving injections of hyaluronic acid during treatment for osteoarthritis experienced better pain relief to standard treatment. The study, involving six study sites and 14 physicians, followed 63 patients over the course of two routine injections of hyaluronic acid for the treatment of osteoarthritis.
During the first treatment, patients either received no local anesthesia or an alternate local anesthesia prior to cannulation or needle puncture. During the second treatment, patients received the LidoSite system, comprised of the LidoSite Patch and the LidoSite Controller. In the study, more than 73% preferred LidoSite to the treatment used during their first visit.
"This initial study demonstrates the acceptability among patients and rheumatologists for using LidoSite as an effective treatment regime for needle pain for the multiple injections arthritis requires, as well as its potential availability in the doctor's office setting," said Timothy McIntyre, president and CEO of Vyteris.
Source: Datamonitor
Related Articles
- Alpharma Reports Positive Results From Phase III Osteoarthritis Pain Study
- Voltaren(R) Gel Receives US Regulatory Approval As the First Approved Topical Prescription Treatment for Pain Associated With Osteoarthritis
- Effective Treatment for Shoulder Pain
- Hadasit Commences Phase II Trial of the Virtual Reality System for the Treatment of Chronic Pain and Stroke Rehabilitation at Hadassah University Hospital
- Avigen Completes Safety, Tolerability and Pharmacokinetic Trial For AV411, a Potential First-in-Class Oral Treatment For Neuropathic Pain; AV411 Phase IIa Study in Australia Continues to Enroll
- New Treatment Guidelines Support Use of FUZEON(R) to Achieve Undetectable HIV in Treatment-Experienced Patients
- SinoFresh Reports Patient Case Study: Allergic Fungal Rhinosinusitis in Adult Male With History of Sinus Conditions
- FemmePharma Global Healthcare, Inc. Opens Investigational New Drug Application for Treatment of Breast Pain
- FDA Accepts Filed Pre-Market Approval Supplement to Expand the Indication for Hyalgan(R) (Sodium Hyaluronate) to Include Shoulder Pain Due to Osteoarthritis
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
 |
 |
User Comments (0)
RSS Feeds